Skip to content

A Trial Evaluating the Role of Sildenafil in the Treatment of Fetal Growth Restriction

A Randomized Controlled Trial Evaluating the Role of Sildenafil in the Treatment of Fetal Growth Restriction

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02590536
Enrollment
90
Registered
2015-10-29
Start date
2015-10-31
Completion date
2017-06-02
Last updated
2017-08-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fetal Growth Retardation

Keywords

Sildenafil, Fetal growth Restriction, Umbilical Artery Doppler

Brief summary

This is a Randomized Controlled Trial to evaluate the effect of sildenafil on Doppler velocity indices of the umbilical arteries in patients with placental insufficiency and fetal growth restriction, and if sildenafil can improve fetal and neonatal outcomes in those patients.

Interventions

DRUGSildenafil citrate

In patients with Fetal Growth Restriction (FGR)and abnormal umbilical artery Doppler, will be randomly assigned and divided to 2 groups which will be treated with sildenafil citrate either placebo. This study will compare the change in Resistance Index (RI) and the Pulsatility Index (PI) of the umbilical artery and fetal middle cerebral artery, for patients who receive 25 mg of oral sildenafil citrate 8 hourly starting at diagnosis of FGR until delivery against those who will receive placebo of the same color and shape of sildenafil citrate tablet.

DRUGplacebo

Sponsors

Ain Shams University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 40 Years
Healthy volunteers
No

Inclusion criteria

* Pregnant women, singleton pregnancy, gestational age 24-34 weeks, with * Fetal growth restriction. * Intact membranes. * Abnormal umbilical artery Doppler waveforms. * Fetal abdominal circumference at or below the tenth percentile. * Normal venous fetal Doppler

Exclusion criteria

* Undetermined gestational age. * Intrauterine infection. * High Risk for aneuploidy (e.g. maternal age ≥40 years, detected congenital fetal anomalies in the current or previous pregnancies). * Maternal cardiovascular morbidity. * Users of any vasodilator agents. * Known allergy to sildenafil citrate

Design outcomes

Primary

MeasureTime frame
The change in Doppler velocity indices( Resistance index (RI) and the pulsatility index (PI) of the umbilical arteries as a Ratio24 weeks to 34 weeks of gestation.
The change in Doppler velocity indices( Resistance index (RI) and the pulsatility index (PI), of fetal middle cerebral artery as a Ratio24 weeks to 34 weeks of gestation.

Secondary

MeasureTime frame
Neonatal birth weight in gramsAt time of Delivery
Gestational age at delivery in weeksAt time of Delivery
Neonatal complication rates including Intraventricular hemorrhage (IVH) , Neonatal Necrotizing Enterocolitis (NEC) , Syndrome Respiratory Distress (RDS) , Neonatal anemia, Neonatal blood transfusion).The first 28 day of delivery
Neonatal ICU admission rateThe first 28 day of delivery

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 21, 2026